Search
Acumen Pharmaceuticals Inc
ABOSAdd to Watchlist
2.120USD
-0.050-2.30%
Close 07-24 16:00（ET）Quotes delayed by 15 min
153.12MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-24The current earnings forecast score of Acumen Pharmaceuticals Inc is 9.33, ranking 6 out of 386 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 10.00 and a low of 4.00.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
7.400
Target Price
+231.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Acumen Pharmaceuticals Inc
ABOS
6
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Acumen Pharmaceuticals Inc's price target?
Analysts forecast that Acumen Pharmaceuticals Inc's price target is USD 6.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Acumen Pharmaceuticals IncABOS's recent earnings per share performed?
The market expectation was USD -0.33, while Acumen Pharmaceuticals IncABOS's earnings per share (EPS) for the previous quarter was USD -0.41. EPS for the next quarter is expected at USD -0.37.
What is the analyst rating for Acumen Pharmaceuticals Inc?
Based on the ratings of Acumen Pharmaceuticals Inc's stock from 6 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.